Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences
  • Register
  • Login

Urology Journal

  • Home
  • Instant Online
    • Instant 2026
    • Instant 2023
    • Instant 2021
    • Instant 2020
  • Current
  • Archives
  • Announcements
  • Submissions
  • Author Guidelines
  • About
    • About the Journal
    • Editorial Team
    • Privacy Statement
    • Contact
Advanced Search
  1. Home
  2. Archives
  3. Vol. 6 No. 2 (2009): Spring
  4. ORIGINAL PAPER(UROLOGICAL ONCOLOGY)

Vol. 6 No. 2 (2009)

May 2009

Expression of Survivin and Its Spliced Variants in Bladder Tumors as a Potential Prognostic Marker

  • Nazila Nouraee
  • Seyed Javad Mowla
  • Ardalan Ozhand
  • Mahmoud Parvin
  • Seyed Amir Mohsen Ziaee
  • Nasim Hatefi

Urology Journal, Vol. 6 No. 2 (2009), 27 May 2009 , Page 101-108
https://doi.org/10.22037/uj.v6i2.251 Published: 2009-05-26

  • View Article
  • Download
  • Cite
  • Statastics
  • Share

Abstract

Introduction: Survivin, a novel inhibitor of apoptosis, is re-expressed in a vast majority of human cancers and is widely considered as a diagnostic marker of cancers. Survivin protein regulates both cell division and apoptosis. There are at least 5 spliced variants of the gene with different subcellular localization and anti-apoptotic property. We examined the expression pattern of survivin and its 2 spliced variants, survivin-?Ex3 and survivin-2B, and their prognostic values in archival collections of formalin-fixed paraffin-embedded samples of bladder tumors.

Materials and Methods: Total RNA from formalin-fixed paraffin-embedded samples (51 samples from 30 patients with bladder cancer and 5-year follow-up) were extracted and analyzed by semiquantitative reverse transcriptase polymerase chain reaction technique. Tissue distribution and subcellular localization of survivin protein in tumor tissues was also examined by immunohistochemistry.

Results: The expression of survivin, survivin-?Ex3, and survivin-2B were detected in 66.6%, 47.8%, and 54.7% of the specimens, respectively. The expression of survivin and survivin-?Ex3 were preferentially elevated in tumors with higher grades, whereas survivin-2B expression was lower in high-grade tumors (P = .04). A reverse correlation was observed between survivin-2B expression and high-grade tumors. Immunohistochemistry results also confirmed the nuclear localization of survivin protein within tumoral cells.

Conclusion: We were successful in detecting the expression of survivin and its variants in formalin-fixed paraffin-embedded bladder samples. Furthermore, our results showed that overexpression of survivin and survivin-?Ex3 in bladder tumors correlates with poor prognosis of bladder cancer. We suggest that survivin and its variants are suitable prognostic markers of bladder tumors.

  • PDF

How to Cite

Nouraee, N., Mowla, S. J., Ozhand, A., Parvin, M., Ziaee, S. A. M., & Hatefi, N. (2009). Expression of Survivin and Its Spliced Variants in Bladder Tumors as a Potential Prognostic Marker. Urology Journal, 6(2), 101–108. https://doi.org/10.22037/uj.v6i2.251
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX
  • Abstract Viewed: 313 times
  • PDF Downloaded: 213 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Information

  • For Readers
  • For Authors

Developed By

Open Journal Systems
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact
Powered by OJSPlus